Search

Displaying results 3951 - 3960 of 10000 in total
  1. Drug

    Apc001

    go.drugbank.com/drugs/DB17819
    Experimental

    Apc001 is an aptamer developed for the treatment of osteogenesis imperfecta.

  2. Drug

    HLX-58

    go.drugbank.com/drugs/DB18699
    Experimental

    HLX-58 is an investigational monoclonal antibody targeted against claudin 18.2.

  3. Drug

    BA1301

    go.drugbank.com/drugs/DB19390
    Investigational

    BA1301 is an anti-Claudin18.2 monoclonal antibody conjugated with Duostatin-5.

  4. Drug

    CA-170

    go.drugbank.com/drugs/DB15772
    Investigational

    CA-170 is a selective, small molecule inhibitor of PD-L1.

  5. Drug

    Tagetitoxin

    go.drugbank.com/drugs/DB04788
    Experimental

    Tagetitoxin is a bacterial phytotoxin. It preferentially inhibits eukaryotic RNA polymerase.

  6. Drug

    Clorobiocin

    go.drugbank.com/drugs/DB03966
    Experimental

    Clorobiocin is an aminocoumarin antibiotic, similar to [novobiocin] and coumermycin A1.

  7. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    [A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time. … Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.

  8. Drug

    Ularitide

    go.drugbank.com/drugs/DB05034
    Investigational

    Ularitide is a synthetic form of urodilatin, a naturally occurring human natriuretic peptide that is involved in regulating blood pressure and the excretion of water and sodium from the kidneys. … Ularitide is currently in Phase 2 development as a potential treatment for patients with acute decompensated heart failure (ADHF).

  9. Drug

    VT-111

    go.drugbank.com/drugs/DB05646
    Investigational

    VT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.

  10. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    an IgG2 framework. … occurs in a pH-dependent manner[A218551] - this allows satralizumab to bind an IL-6 receptor until it reaches an endosome, after which the drug may dissociate from the receptor and move back into the